Welcome to our dedicated page for Prelude Therapeutics news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics stock.
Prelude Therapeutics Incorporated reports news around its precision oncology pipeline, including clinical and preclinical programs aimed at genetically and epigenetically defined cancer targets. Recurring updates cover PRT12396, a mutant-selective JAK2V617F inhibitor being developed for certain myeloproliferative neoplasms, and PRT13722, an orally bioavailable selective KAT6A degrader being developed in breast cancer.
Company announcements also address FDA and IND-related developments, preclinical data presentations at oncology and hematology meetings, financial results, investor presentations, executive appointments, and capital-structure activity tied to its Nasdaq-listed common stock.
Prelude Therapeutics (PRLD) will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York City, held September 14-16, 2026. On September 16, 2026, at 10:30 a.m. ET, members of the executive team will join a fireside chat. A live webcast and a 90-day archive of the session will be available on the company’s website under Events and Presentations.
Prelude Therapeutics (PRLD) received FDA clearance of its Investigational New Drug (IND) application for PRT13722, a first-in-class oral KAT6A selective degrader for HR-positive, HER2-negative breast cancer. The clearance allows Prelude to initiate a first-in-human Phase 1 clinical trial, with patient enrollment expected to begin in the fourth quarter of 2026.
The Phase 1, open-label, multicenter study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of PRT13722 in adults with locally advanced or metastatic HR+/HER2- breast cancer. The trial will assess PRT13722 as both monotherapy and in combination with endocrine and targeted therapies. Prelude discovered and is developing highly selective, orally bioavailable KAT6A degraders and believes sparing KAT6B may offer improved efficacy, tolerability and combinability compared with dual KAT6A/B inhibitors.
Prelude Therapeutics (Nasdaq: PRLD) reported second quarter 2026 results and pipeline progress. As of June 30, 2026, the company held $155.2 million in cash, cash equivalents, restricted cash and marketable securities and expects its current cash runway to extend into the second quarter of 2028.
Q2 2026 revenue was $5.7 million versus none a year earlier. Research and development expenses fell to $16.1 million from $25.8 million, and general and administrative expenses decreased to $5.0 million from $6.4 million. Net loss narrowed to $13.9 million ($0.14/share) from $31.2 million ($0.41/share).
Pipeline updates included plans to initiate a Phase 1 study of PRT13722, a KAT6A degrader for HR+ breast cancer, in Q4 2026, ongoing enrollment in the Phase 1 study of PRT12396 for PV and MF under an exclusive option agreement with Incyte, and continued advancement of the wholly owned mCALR DAC discovery program and degrader payloads for next-generation DAC partnerships.
Prelude Therapeutics (Nasdaq: PRLD) reported Q1 2026 results and pipeline progress.
Cash, cash equivalents, restricted cash and marketable securities were $84.8 million on March 31, 2026, plus approximately $90 million gross proceeds from a recent offering, extending cash runway into the second quarter of 2028.
The company began Phase 1 enrollment for PRT12396 in PV and MF, advanced KAT6A degrader PRT13722 toward an expected mid‑2026 IND and 2H 2026 Phase 1, and expanded its degrader antibody conjugate platform and mCALR program.
Q1 2026 R&D expense was $13.6 million and G&A expense $5.2 million; net loss was $10.4 million, or $0.13 per share.
Prelude Therapeutics (Nasdaq: PRLD) priced an underwritten offering of 18,018,014 shares at $4.44 per share and pre-funded warrants for up to 2,252,252 shares at $4.4399 each, generating approximately $90.0 million in gross proceeds.
The offering is expected to close on or about April 21, 2026, was led by RA Capital, and the company intends to use net proceeds for general corporate purposes, including research and clinical development.
Prelude Therapeutics (Nasdaq: PRLD) presented preclinical data for PRT13722, a first-in-class, orally bioavailable, potent and selective KAT6A degrader, showing complete tumor regressions as monotherapy in HR+/HER2- CDX and PDX models and an improved preclinical hematological safety profile versus prifetrastat. Prelude is on track to file an IND in mid-2026 and, pending clearance, to start a Phase 1 clinical trial in 2H 2026.
Prelude Therapeutics (Nasdaq: PRLD) appointed Dr. Charles Morris as Chief Medical Officer effective April 20, 2026. Dr. Morris brings over 30 years of oncology drug development experience and a track record contributing to multiple drug approvals.
The company said its two lead programs targeting myeloproliferative neoplasms and ER+ breast cancer are expected to enter clinical development in 2026, and Dr. Morris will oversee clinical strategy and execution.
Prelude Therapeutics (Nasdaq: PRLD) announced acceptance of a preclinical poster for its first‑in‑class oral KAT6A selective degrader, PRT13722, at the AACR Annual Meeting (April 17–22, 2026).
The poster reports complete tumor regressions as monotherapy and an improved preclinical hematological safety profile. The company selected a development candidate, expects to file an IND in mid‑2026, and plans to start phase 1 in H2 2026.
Prelude Therapeutics (NASDAQ: PRLD) reported full‑year 2025 results and R&D updates on March 10, 2026. Key developments: IND clearance for PRT12396 (mutant‑selective JAK2V617F) with Phase 1 start anticipated Q2 2026, and an IND for PRT13722 (KAT6A degrader) planned mid‑2026. Cash and equivalents were $106.4M at year‑end, funding operations into Q2 2027.
R&D expense fell to $94.3M, G&A to $22.4M, and net loss narrowed to $99.5M ($1.29/sh).
Prelude Therapeutics (Nasdaq: PRLD) announced FDA clearance of its IND for PRT12396, a mutant-selective JAK2V617F inhibitor, enabling a Phase 1 open-label study in high-risk polycythemia vera and intermediate/high-risk myelofibrosis.
The company anticipates dosing the first patient by Q2 2026 and notes an exclusive option agreement with Incyte from November 2025.